Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Accumulated Depreciation (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Accumulated Depreciation for 6 consecutive years, with $21.6 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation rose 15.32% to $21.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.6 million through Dec 2025, up 15.32% year-over-year, with the annual reading at $21.6 million for FY2025, 15.32% up from the prior year.
  • Accumulated Depreciation for Q4 2025 was $21.6 million at TScan Therapeutics, up from $18.7 million in the prior quarter.
  • The five-year high for Accumulated Depreciation was $21.6 million in Q4 2025, with the low at $5.1 million in Q4 2021.
  • Average Accumulated Depreciation over 5 years is $14.0 million, with a median of $14.6 million recorded in 2023.
  • The sharpest move saw Accumulated Depreciation surged 189.63% in 2021, then increased 15.32% in 2025.
  • Over 5 years, Accumulated Depreciation stood at $5.1 million in 2021, then soared by 101.06% to $10.2 million in 2022, then skyrocketed by 42.83% to $14.6 million in 2023, then rose by 28.14% to $18.7 million in 2024, then increased by 15.32% to $21.6 million in 2025.
  • According to Business Quant data, Accumulated Depreciation over the past three periods came in at $21.6 million, $18.7 million, and $14.6 million for Q4 2025, Q4 2024, and Q4 2023 respectively.